RHOA and neoplasm: In support of this assertion, tumour cells injected into mice models and treated with blebbistatin, an inhibitor of the RhoA downstream effector myosin II, exhibited reduced intravascular survival and subsequently arrest, which could explain the delay on metastatic onset that was observed.